Disodium cromoglycate inhibits asthma-like features induced by sphingosine-1-phosphate

Fiorentina Roviezzo, Rosalinda Sorrentino, Valentina Mattera Iacono, Vincenzo Brancaleone, Michela Terlizzi, Maria Antonietta Riemma, Antonio Bertolino, Antonietta Rossi, Maria Matteis, Giuseppe Spaziano, Aldo Pinto, Bruno D'Agostino, Giuseppe Cirino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Compelling evidence suggests the involvement of sphingosine-1-phosphate (S1P) in the pathogenesis of asthma. The systemic administration of S1P causes asthma like features in the mouse involving mast cells. In this study we investigated whether disodium cromoglycate (DSCG), administered as a preventative treatment as in human therapy, could affect S1P effects on airways. BALB/c mice, treated with DSCG, received subcutaneous administration of S1P. Bronchi and pulmonary tissues were collected and functional, molecular and cellular studies were performed. DSCG inhibited S1P-induced airway hyper-reactivity as well as pulmonary inflammation. DSCG decreased the recruitment of solely mast cells and B cells in the lung. IgE serum levels, prostaglandin D2, mucus production and IL-13 were also reduced when mice were pretreated with DSCG. S1P induced pulmonary expression of CD23 on T and B cells, that was reversed by DSCG. Conversely, S1P failed to upregulate CD23 in mast cell-deficient Kit W−sh/W−sh mice. In conclusion we have shown that DSCG inhibits S1P-induced asthma like features in the mouse. This beneficial effect is due to a regulatory action on mast cell activity, and in turn to an inhibition of IgE-dependent T and B cells responses.

Original languageEnglish
Pages (from-to)626-635
Number of pages10
JournalPharmacological Research
Volume113
DOIs
Publication statusPublished - Nov 1 2016
Externally publishedYes

Fingerprint

Cromolyn Sodium
Asthma
Mast Cells
B-Lymphocytes
Lung
Immunoglobulin E
T-Lymphocytes
Prostaglandin D2
Interleukin-13
sphingosine 1-phosphate
Bronchi
Mucus
Pneumonia
Up-Regulation

Keywords

  • CD23
  • Cromoglycate
  • IgE
  • Mast cell
  • S1P

ASJC Scopus subject areas

  • Pharmacology

Cite this

Roviezzo, F., Sorrentino, R., Iacono, V. M., Brancaleone, V., Terlizzi, M., Riemma, M. A., ... Cirino, G. (2016). Disodium cromoglycate inhibits asthma-like features induced by sphingosine-1-phosphate. Pharmacological Research, 113, 626-635. https://doi.org/10.1016/j.phrs.2016.09.014

Disodium cromoglycate inhibits asthma-like features induced by sphingosine-1-phosphate. / Roviezzo, Fiorentina; Sorrentino, Rosalinda; Iacono, Valentina Mattera; Brancaleone, Vincenzo; Terlizzi, Michela; Riemma, Maria Antonietta; Bertolino, Antonio; Rossi, Antonietta; Matteis, Maria; Spaziano, Giuseppe; Pinto, Aldo; D'Agostino, Bruno; Cirino, Giuseppe.

In: Pharmacological Research, Vol. 113, 01.11.2016, p. 626-635.

Research output: Contribution to journalArticle

Roviezzo, F, Sorrentino, R, Iacono, VM, Brancaleone, V, Terlizzi, M, Riemma, MA, Bertolino, A, Rossi, A, Matteis, M, Spaziano, G, Pinto, A, D'Agostino, B & Cirino, G 2016, 'Disodium cromoglycate inhibits asthma-like features induced by sphingosine-1-phosphate', Pharmacological Research, vol. 113, pp. 626-635. https://doi.org/10.1016/j.phrs.2016.09.014
Roviezzo F, Sorrentino R, Iacono VM, Brancaleone V, Terlizzi M, Riemma MA et al. Disodium cromoglycate inhibits asthma-like features induced by sphingosine-1-phosphate. Pharmacological Research. 2016 Nov 1;113:626-635. https://doi.org/10.1016/j.phrs.2016.09.014
Roviezzo, Fiorentina ; Sorrentino, Rosalinda ; Iacono, Valentina Mattera ; Brancaleone, Vincenzo ; Terlizzi, Michela ; Riemma, Maria Antonietta ; Bertolino, Antonio ; Rossi, Antonietta ; Matteis, Maria ; Spaziano, Giuseppe ; Pinto, Aldo ; D'Agostino, Bruno ; Cirino, Giuseppe. / Disodium cromoglycate inhibits asthma-like features induced by sphingosine-1-phosphate. In: Pharmacological Research. 2016 ; Vol. 113. pp. 626-635.
@article{86afd3f211c5491689738b4e475b620a,
title = "Disodium cromoglycate inhibits asthma-like features induced by sphingosine-1-phosphate",
abstract = "Compelling evidence suggests the involvement of sphingosine-1-phosphate (S1P) in the pathogenesis of asthma. The systemic administration of S1P causes asthma like features in the mouse involving mast cells. In this study we investigated whether disodium cromoglycate (DSCG), administered as a preventative treatment as in human therapy, could affect S1P effects on airways. BALB/c mice, treated with DSCG, received subcutaneous administration of S1P. Bronchi and pulmonary tissues were collected and functional, molecular and cellular studies were performed. DSCG inhibited S1P-induced airway hyper-reactivity as well as pulmonary inflammation. DSCG decreased the recruitment of solely mast cells and B cells in the lung. IgE serum levels, prostaglandin D2, mucus production and IL-13 were also reduced when mice were pretreated with DSCG. S1P induced pulmonary expression of CD23 on T and B cells, that was reversed by DSCG. Conversely, S1P failed to upregulate CD23 in mast cell-deficient Kit W−sh/W−sh mice. In conclusion we have shown that DSCG inhibits S1P-induced asthma like features in the mouse. This beneficial effect is due to a regulatory action on mast cell activity, and in turn to an inhibition of IgE-dependent T and B cells responses.",
keywords = "CD23, Cromoglycate, IgE, Mast cell, S1P",
author = "Fiorentina Roviezzo and Rosalinda Sorrentino and Iacono, {Valentina Mattera} and Vincenzo Brancaleone and Michela Terlizzi and Riemma, {Maria Antonietta} and Antonio Bertolino and Antonietta Rossi and Maria Matteis and Giuseppe Spaziano and Aldo Pinto and Bruno D'Agostino and Giuseppe Cirino",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.phrs.2016.09.014",
language = "English",
volume = "113",
pages = "626--635",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Disodium cromoglycate inhibits asthma-like features induced by sphingosine-1-phosphate

AU - Roviezzo, Fiorentina

AU - Sorrentino, Rosalinda

AU - Iacono, Valentina Mattera

AU - Brancaleone, Vincenzo

AU - Terlizzi, Michela

AU - Riemma, Maria Antonietta

AU - Bertolino, Antonio

AU - Rossi, Antonietta

AU - Matteis, Maria

AU - Spaziano, Giuseppe

AU - Pinto, Aldo

AU - D'Agostino, Bruno

AU - Cirino, Giuseppe

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Compelling evidence suggests the involvement of sphingosine-1-phosphate (S1P) in the pathogenesis of asthma. The systemic administration of S1P causes asthma like features in the mouse involving mast cells. In this study we investigated whether disodium cromoglycate (DSCG), administered as a preventative treatment as in human therapy, could affect S1P effects on airways. BALB/c mice, treated with DSCG, received subcutaneous administration of S1P. Bronchi and pulmonary tissues were collected and functional, molecular and cellular studies were performed. DSCG inhibited S1P-induced airway hyper-reactivity as well as pulmonary inflammation. DSCG decreased the recruitment of solely mast cells and B cells in the lung. IgE serum levels, prostaglandin D2, mucus production and IL-13 were also reduced when mice were pretreated with DSCG. S1P induced pulmonary expression of CD23 on T and B cells, that was reversed by DSCG. Conversely, S1P failed to upregulate CD23 in mast cell-deficient Kit W−sh/W−sh mice. In conclusion we have shown that DSCG inhibits S1P-induced asthma like features in the mouse. This beneficial effect is due to a regulatory action on mast cell activity, and in turn to an inhibition of IgE-dependent T and B cells responses.

AB - Compelling evidence suggests the involvement of sphingosine-1-phosphate (S1P) in the pathogenesis of asthma. The systemic administration of S1P causes asthma like features in the mouse involving mast cells. In this study we investigated whether disodium cromoglycate (DSCG), administered as a preventative treatment as in human therapy, could affect S1P effects on airways. BALB/c mice, treated with DSCG, received subcutaneous administration of S1P. Bronchi and pulmonary tissues were collected and functional, molecular and cellular studies were performed. DSCG inhibited S1P-induced airway hyper-reactivity as well as pulmonary inflammation. DSCG decreased the recruitment of solely mast cells and B cells in the lung. IgE serum levels, prostaglandin D2, mucus production and IL-13 were also reduced when mice were pretreated with DSCG. S1P induced pulmonary expression of CD23 on T and B cells, that was reversed by DSCG. Conversely, S1P failed to upregulate CD23 in mast cell-deficient Kit W−sh/W−sh mice. In conclusion we have shown that DSCG inhibits S1P-induced asthma like features in the mouse. This beneficial effect is due to a regulatory action on mast cell activity, and in turn to an inhibition of IgE-dependent T and B cells responses.

KW - CD23

KW - Cromoglycate

KW - IgE

KW - Mast cell

KW - S1P

UR - http://www.scopus.com/inward/record.url?scp=84990199419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990199419&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2016.09.014

DO - 10.1016/j.phrs.2016.09.014

M3 - Article

AN - SCOPUS:84990199419

VL - 113

SP - 626

EP - 635

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -